Peer Reviewed

1

Document Type

Article

Publication Date

1-5-2015

Keywords

Biomarkers, Tumor, Humans, Lung Diseases, MicroRNAs, RNA, Long Noncoding

Funder/Sponsor

Health Research Board in Ireland. National Children's Research Centre. European Respiratory Society/GlaxoSmithKline

Comments

This article has been accepted for publication in Thorax following peer review. The definitive copyedited, typeset version Vencken SF, Greene CM*, McKiernan PJ. Non-coding RNA as lung disease biomarkers. Thorax. 2015 May;70(5):501-3 is available online at: www. http://thorax.bmj.com/content/70/5/501.long

Abstract

Biomarkers are quantifiable indicators of disease. These surrogates should be specific, sensitive, predictive, robust and easily accessible. A major class of RNA described as non-coding RNA fulfils many of these criteria, and recent studies have demonstrated that the two major subclasses of non-coding RNA, long non-coding RNA and, in particular, microRNA are promising potential biomarkers. The ability to detect non-coding RNAs in biofluids has highlighted their usefulness as non-invasive markers of lung disease. Because expression of specific non-coding RNAs is altered in many lung diseases and their levels in the circulation often reflect the changes in expression of their lung-specific counterparts, exploiting these biomolecules as diagnostic tools seems an obvious goal. New technology is driving developments in this area and there has been significant recent progress with respect to lung cancer diagnostics. The non-coding RNA biomarker field represents a clear example of modern-day bench-to-bedside research.

Disciplines

Medicine and Health Sciences

Citation

Vencken SF, Greene CM, McKiernan PJ. Non-coding RNA as lung disease biomarkers. Thorax. 2015;70(5):501-3.

PubMed ID

25550385

DOI Link

10.1136/thoraxjnl-2014-206193

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 4.0 License.

Share

COinS